Navigation Links
$1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope
Date:9/11/2008

WALNUT CREEK, Calif., Sept. 11 /PRNewswire/ -- A project to advance research and improve treatments for fragile X syndrome will be funded by a new $1.6 million, three-year cooperative agreement with the Center for Disease Control (CDC) and others.

The agreement, intended to bring better care to the more than 100,000 affected Americans, is between The National Fragile X Foundation (NFXF), the CDC's National Center on Birth Defects and Developmental Disabilities, the Association of University Centers on Disabilities, the New York State Institute for Basic Research in Developmental Disabilities and the Data Coordinating Center at Columbia University.

Fragile X syndrome is the most common known cause of inherited intellectual disability and the most common known single gene cause of autism.

The effort will advance the core activities of the Fragile X Clinical and Research Consortium (FXCRC). The NFXF initiated the FXCRC in 2006 to advance clinical practice and facilitate coordinated, collaborative multi-site research. The FXCRC has been meeting regularly since its inception to address best practices in evaluation and treatment, including pharmacological, therapeutic and educational treatments, strategies for supporting and enhancing clinic work, and research priorities. The NFXF prioritized its support of a clinics consortium when it realized the body of Fragile X expertise was scattered throughout North America and organizing that expertise would enhance existing and future research efforts while simultaneously making clinical evaluation and treatment more easily accessible to families.

"The fact the consortium has moved from concept to reality to government funding so quickly is a testament to the organization, its leadership and the families that each year travel to Washington, D.C., to urge Congress to support this important cause," said Jeffrey Cohen, chair, NFXF Public Policy Committee, and father of a son and daughter with fragi
'/>"/>

SOURCE The National Fragile X Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
2. Yongye Biotechnology International Raises $9.4 Million in Private Placement
3. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
6. Proteolix Raises $79 Million in Series C Financing
7. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
8. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
9. Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
10. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
11. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
...s (CTI),(Nasdaq and MTA: CTIC) announced today tha...hareholders on February 27, 2009 in lieu of the Sp...o take place on February 6, 2009.,Shareholders of ...9, the,record date established by the Board of Dir...eting. Updated proxy materials, including an updat...
... (Nasdaq: NVAX ) a clinical-stage vaccine compan...d Chief Medical Officer, will be presenting at the...nce on January 26, 2009 at the Grand Hyatt in Wash...cus Session ,What benefits are single-use technolo...ns providing in practice, and will be speaking to ...
... with Acute Spinal Cord Injury , Geron Corpora...d and Drug,Administration (FDA) has granted cleara...) application for the clinical trial of GRNOPC1 in...ance enables Geron to move forward with,the world,...l-based therapy,in man. , Geron plans to initi...
Other Biology Technology:Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 3MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy 2
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Research is vital to a cleaner, greener, low carbon future 2By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 1By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 1Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 4Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 5Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 1Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 3
...e fast disappearing from restaurant menus as stock... While the reasons for the eel decline remain as m...y a NOAA scientist and colleagues in Japan and the...nditions may be a primary factor in declining repr...ects of spawning and early life history of this sp...
...t of champions? That would be a soy protein-packed...ements for three different FDA health claims and l...at again until lunch. , University of Illinois sc...st such a cereal, one thats passed the taste test ...asons to eat soy--and even more reasons to consume...
...pleased to announce the launch of the Internationa...llows on the heels of the Panda Genome workshop he...Hongmei Zhu, a scientist from BGI-Shenzhen, stated...sequencing and assembling of the draft sequence wi...ved animal all over the world and is considered a ...
Other Biology News:Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 2Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 3U of I researcher develops power-packed soy breakfast cereal 2Giant panda genome to be sequenced 2Giant panda genome to be sequenced 3
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer* from Molecular Probes (Invitrogen)
ER-beta Fluorescence polarization Assay Kit from Invitrogen
GIBCO MEM Non-Essential Amino Acids Solution 10 mM (100X), liquid from Invitrogen
...rains are K-12 derivatives that have mutations in ...one reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielde... even though overall expression levels were simila...
Biology Products: